Threatening drug-drug interaction in a kidney transplant patient with coronavirus disease 2019 (COVID-19). [electronic resource]
Producer: 20200813Description: e13286 p. digitalISSN:- 1399-3062
- Adult
- Antiviral Agents -- adverse effects
- Betacoronavirus
- C-Reactive Protein -- immunology
- COVID-19
- Ciliopathies -- complications
- Cobicistat -- therapeutic use
- Common Cold -- etiology
- Coronavirus Infections -- complications
- Cough -- etiology
- Cytochrome P-450 CYP3A Inhibitors -- adverse effects
- Darunavir -- therapeutic use
- Deprescriptions
- Drug Combinations
- Drug Interactions
- Enzyme Inhibitors -- therapeutic use
- Fatigue -- etiology
- Female
- Glucocorticoids -- therapeutic use
- Graft Rejection -- prevention & control
- Humans
- Hydroxychloroquine -- therapeutic use
- Immunocompromised Host -- immunology
- Immunosuppressive Agents -- adverse effects
- Interleukin-10 -- immunology
- Interleukin-1beta -- immunology
- Interleukin-6 -- immunology
- Interleukin-8 -- immunology
- Kidney Diseases, Cystic -- complications
- Kidney Failure, Chronic -- etiology
- Kidney Transplantation
- Leber Congenital Amaurosis -- complications
- Lopinavir -- adverse effects
- Methylprednisolone -- therapeutic use
- Optic Atrophies, Hereditary -- complications
- Pandemics
- Pneumonia, Viral -- complications
- Ritonavir -- adverse effects
- SARS-CoV-2
- Severity of Illness Index
- Tacrolimus -- adverse effects
- COVID-19 Drug Treatment
No physical items for this record
Publication Type: Case Reports; Journal Article
There are no comments on this title.
Log in to your account to post a comment.